Italia markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
87,94+1,24 (+1,42%)
In data: 11:30AM EDT. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente86,71
Aperto87,40
Denaro87,70 x 200
Lettera88,03 x 200
Min-Max giorno86,89 - 88,32
Intervallo di 52 settimane85,21 - 125,83
Volume109.370
Media Volume593.175
Capitalizzazione21,194B
Beta (5 anni mensile)0,23
Rapporto PE (ttm)21,45
EPS (ttm)4,10
Prossima data utili06 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendo02 giu 2022
Stima target 1A118,53
  • GlobeNewswire

    BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023

    Program updates include new data for investigational CAR-T and ex-vivo T cell therapies, a novel ADC, a FixVac off-the-shelf mRNA cancer vaccine, and a bi-specific antibody New data from BioNTech’s investigational autologous CAR-T therapy BNT211 demonstrate the potential of the Company’s innovative approach of combining an autologous CAR-T cell therapy targeting Claudin-6 (“CLDN6”) with a CLDN6-encoding CAR-T cell amplifying mRNA vaccine (“CARVac”)First-in-human data from Phase 1/2 study with ne

  • GlobeNewswire

    Update Regarding Pfizer’s Statement on COMIRNATY-Related Write-Offs

    MAINZ, Germany, October 16, 2023 (GLOBE NEWSWIRE) -- On October 13, 2023, Pfizer Inc. (NYSE: PFE, “Pfizer”), a collaboration partner of BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), announced a non-cash charge for inventory write-offs and other charges related to COMIRNATY of $0.9 billion. The Company has been informed by Pfizer that the majority of the write-offs relate to raw materials, mainly formulation-related lipids, purchased during the pandemic, as well as COVID-19 vaccine dos

  • GlobeNewswire

    Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine

    COMIRNATY Omicron XBB.1.5-adapted monovalent COVID-19 vaccine is now authorized in Canada for individuals 6 months of age and olderNew Omicron XBB.1.5-adapted COVID-19 vaccine is administered as a single dose for individuals 5 years of age and older, regardless of COVID-19 vaccination history. In children 6 months through 4 years of age the vaccine is administered as a three-dose series in those without a history of completion of a COVID-19 primary vaccination course, or as a single dose in thos